Drug Profile
Research programme: phosphodiesterase 10A inhibitors - Amgen/Memory Pharmaceuticals
Alternative Names: Phosphodiesterase 10 inhibitors - Amgen/MemoryLatest Information Update: 12 Feb 2010
Price :
$50
*
At a glance
- Originator Memory Pharmaceuticals
- Developer Amgen; Memory Pharmaceuticals
- Class Small molecules
- Mechanism of Action Phosphodiesterase 10A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Neurological disorders; Psychiatric disorders
Most Recent Events
- 12 Mar 2008 Memory Pharmaceuticals amends its collaboration agreement with Amgen regarding this programme
- 17 Oct 2005 Preclinical trials in Neurological disorders in USA (PO)